MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Ocugen

< Previous 1 2 3 4 5 Next >
News headline image
Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen, Inc. Announces Proposed Public Offering of Common Stock
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen to Present at BIO International Convention 2024
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Set to Join Russell 3000® Index Effective June 28, 2024
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Provides Business Update with First Quarter 2024 Financial Results
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen to Present at May 2024 Investor Conferences
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Provides Business Update with Certain Financials for the Year Ending 2023
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen to Host Conference Call on Tuesday, April 2 at 8:30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023
From Ocugen
Via GlobeNewswire
Tickers OCGN
News headline image
Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer
From Ocugen
Via GlobeNewswire
Tickers OCGN
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story